In partnership with
The White House announced a sweeping new initiative Thursday designed to make in vitro fertilization (IVF) more affordable for millions of Americans. Under the plan, the administration will partner with German pharmaceutical giant Merck KGaA and its U.S. arm EMD Serono to slash prices for three major fertility drugs through a new federal platform called TrumpRx.
President Donald Trump said the deal would cut costs for common fertility medications by as much as 70 to 84 percent, dramatically lowering one of the largest expenses for couples seeking IVF treatment.
“This is about hope, family, and the American dream,” Trump said. “For the first time, millions of families struggling with infertility will have real access to affordable IVF care.”
Massive Discounts on Key IVF Medications
The TrumpRx program—set to launch in January 2026—will list three high-demand fertility drugs at unprecedented discounts:
Gonal-F, a hormone that stimulates egg production
Ovidrel, used to trigger ovulation
Cetrotide, which prevents premature ovulation during treatment
Currently, these medications cost patients about $5,000 per IVF cycle. Under the new pricing model, that number could drop to around $1,000 to $1,500, depending on dosage and treatment needs.
In exchange for the steep price cuts, EMD Serono will receive temporary tariff relief and commit to expanding its U.S. manufacturing and research footprint. The company is also expected to seek accelerated FDA review for a new fertility drug already approved in Europe, signaling potential for future additions to the TrumpRx marketplace.
Administration officials described the deal as part of a broader push to increase fertility care access while bringing pharmaceutical production back to the U.S.
Encouraging Employers to Offer IVF Benefits
Alongside the TrumpRx announcement, the White House introduced a voluntary employer program to expand fertility coverage in workplace insurance plans.
Companies will soon be able to offer stand-alone IVF benefits, separate from traditional health coverage—similar to how dental or vision insurance works. The administration hopes this model will encourage smaller businesses, which often skip fertility coverage, to offer new options without raising overall health plan costs.
Officials said the initiative could become one of the most significant expansions of IVF access in U.S. history, given that roughly 60 percent of women aged 30 to 44 get their health insurance through an employer.
“This is a competitive advantage for businesses and a life-changing benefit for families,” said Dr. Mehmet Oz, the administration’s Medicare and Medicaid chief. “It allows companies to attract and retain talent while helping employees start the families they’ve dreamed of.”
However, participation remains voluntary—there is no federal mandate requiring employers or insurers to provide IVF coverage.
The Reality Behind the Promise
While the TrumpRx deal represents the largest government effort yet to reduce IVF drug prices, fertility experts caution that it only addresses part of the cost problem.
An IVF cycle can range from $20,000 to $30,000, including medications, lab procedures, genetic testing, and clinical monitoring. Drugs typically account for about 20 percent of that total. Reducing medication costs could make treatment more attainable, but many couples will still struggle with the broader financial burden.
Dr. Serena Chen, a New Jersey-based reproductive endocrinologist, welcomed the price cuts but called the policy “a first step, not a full solution.”
“Fertility care—including IVF—is health care,” Chen said. “Discounting drugs helps, but what we really need is a federal mandate for comprehensive fertility insurance coverage.”
Chen also questioned why only EMD Serono is participating, since other leading manufacturers—Organon and Ferring Pharmaceuticals—have yet to join. Without broader industry buy-in, patients using other IVF medications could see little benefit.
Challenges Ahead
Some industry observers warn that increased affordability could strain the existing fertility care system. Clinics are already operating near capacity in many states, and demand for IVF is expected to climb sharply if drug prices fall.
Dr. David Sable, a former fertility specialist turned biotech investor, cautioned that lower prices alone aren’t enough.
“If you make IVF affordable tomorrow, you need the infrastructure and innovation to serve all those patients,” he said. “We need automation, staffing, and oversight to ensure success rates and safety remain high.”
Critics also point to recent budget cuts at the Centers for Disease Control and Prevention, which eliminated a small team that tracked IVF outcomes and safety data nationwide. Without that monitoring, some worry that the surge in fertility treatments could outpace regulatory capacity.
Looking Forward
The TrumpRx launch marks a significant political and economic milestone in the evolving landscape of U.S. fertility care. Supporters see it as a long-overdue intervention that could reshape how Americans pay for IVF medications. Detractors call it an incomplete fix that doesn’t address larger systemic issues like insurance gaps and clinical access.
Still, few dispute that the White House’s fertility initiative—paired with employer-based benefit expansions—could make 2026 a turning point for reproductive health policy.
Whether the plan lives up to its promise will depend on how many pharmaceutical companies join, how employers respond, and whether costs for the rest of the IVF process follow the same downward trend.
For now, the TrumpRx deal represents a major symbolic win for families hoping to build their futures—and a reminder that in the high-stakes world of fertility care, price truly matters.
Key Takeaways
TrumpRx will launch in January 2026 as a new White House–backed drug pricing platform.
The program will offer up to 84% discounts on three major IVF fertility drugs made by EMD Serono.
The initiative aims to make fertility treatments more affordable and expand IVF access nationwide.
Employers will be encouraged to provide optional IVF coverage, similar to dental or vision benefits.
The plan could lower IVF medication costs from $5,000 to around $1,000 per cycle, easing a major barrier for families.
Critics say the move stops short of full insurance coverage mandates for IVF treatments.
The White House hopes the TrumpRx fertility drug discount program will strengthen U.S. family-building options and domestic pharmaceutical manufacturing.
The best HR advice comes from people who’ve been in the trenches.
That’s what this newsletter delivers.
I Hate it Here is your insider’s guide to surviving and thriving in HR, from someone who’s been there. It’s not about theory or buzzwords — it’s about practical, real-world advice for navigating everything from tricky managers to messy policies.
Every newsletter is written by Hebba Youssef — a Chief People Officer who’s seen it all and is here to share what actually works (and what doesn’t). We’re talking real talk, real strategies, and real support — all with a side of humor to keep you sane.
Because HR shouldn’t feel like a thankless job. And you shouldn’t feel alone in it.